Detecting Transitional Cell Carcinoma From Haematuria (TransTuFo)
Status
Conditions
Details and patient eligibility
About
To validate ELISAs for the detection of urinary tissue factor (TF) in patients suspected of having bladder cancer.
Full description
The effective diagnosis of transitional cell carcinoma (TCC), the most common form of bladder cancer, is often quite challenging, due to a lack of disease-specific symptoms. Detecting TCC early is crucial to increase the chances of a cure. Cystoscopy, which is currently the standard test used for urothelial cancer diagnosis, is an invasive and relatively expensive procedure but, while several potential markers in urine have been studied with the goal of replacing cystoscopy, no urinary marker alone or in combination with others has shown sufficient accuracy.
In this study, levels of tissue factor (TF) isoforms will be measured by ELISA in urine samples collected from patients referred to the haematuria clinic with visible or microscopic haematuria. These values will be linked to the subsequent diagnosis of each patient, and used to assess the accuracy of the ELISAs in detecting TCC when compared to standard cystoscopy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Capable of giving written informed consent
- Age ≥18 years
- Referral to haematuria clinic (gross or microscopic haematuria)
Exclusion criteria
- Inability to provide written informed consent
- Previous radiotherapy to the bladder (e.g. prostate cancer)
- Active urinary tract infection (Patients may be re-approached at later opportunity when urinary infection is cleared and haematuria persists)
- Current or planned treatment with neoadjuvant chemotherapy or radiotherapy
- Other known malignant condition, either active or in complete remission ≤5 years
- HIV, hepatitis C, or any other known communicable disease
Trial design
750 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal